Morgan Stanley Maintains Equal-Weight on Acelyrin, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Acelyrin (NASDAQ:SLRN) but reduced the price target from $19 to $13.
November 29, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Acelyrin but lowered the price target from $19 to $13, which may influence investor sentiment and stock price.
A reduction in price target by a major analyst like Morgan Stanley can lead to a negative short-term impact on the stock price as it may reflect a change in the expected performance or valuation of the company. Investors often view such adjustments as a signal to re-evaluate their holdings, which can result in selling pressure.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100